Plenary |
Therapeutic Sessions |
Workshops |
Showcase |
Tuesday, December 1, 2015
7:45am-5:30pm | Registration |
7:45am-8:45am | Pipeline Café |
8:45am | Welcoming Remarks |
9:00am-10:00am |
Opening Plenary Session: Looking for Innovation In the Academic Haystack Moving important therapies from the bench to the bedside is one of the major challenges that faces our industry year in and year out. Experienced leaders from academia, industry and government will look at translational medicine programs past and present and discuss how the stakeholders should best address this issue going forward. Moderator: Mark Simon, Partner, Torreya Partners
|
10:00am-11:00am |
Brain Disease Breakthroughs – Are We at the Tipping Point? Over the last five years the number of drugs being developed for brain and nervous system disorders fell 50% to a dismal 129 as many pharma companies abandoned the pursuit of new brain disease therapies. But recent scientific advances may have turned the tide. Last year investors poured $3.3 billion into companies that are developing drugs for neurodegenerative and psychiatric illnesses. From immunotherapy to gene therapy, and everything in between, which approaches are showing the greatest promise for the treatment of such diseases as depression, Parkinson’s Disease, Alzheimer’s Disease and Multiple Sclerosis? Moderator: Ginger S. Johnson, PhD, Vice President, Defined Health
|
10:00am-11:00am |
Summit Showcase
|
10:00am-12:00pm |
Partnering Forum |
11:00am-12:00pm |
Workshop: For an emerging company, it is often challenging to know when it is time to start looking for a strategic partner. There are many factors to consider – stage of development of a lead asset, intellectual property, management experience, corporate strategy and target market among them. Partnering your assets too soon is like leaving money on the table, but waiting too long can hinder your ability to meet key milestones. This panel will discuss how you will know when it’s the right time to come to the table. Moderator: Lesley Stolz, PhD, Transactions Team, California Innovation Center, Johnson & Johnson Innovation
|
11:00am-12:00pm |
Summit Showcase
|
12:00pm-1:15pm | Lunch with The Experts |
12:00pm-1:15pm | Pipeline Café |
1:15pm-2:15pm |
Immuno-oncology & Precision Medicine: The Double Whammy in Cancer Therapies While immuno-oncology has been hailed as one of the top three cancer therapeutic advances of all time, many believe the greatest benefit will be realized by combining new immunotherapies with drugs that target the pathways that drive cancer cell growth. Join our panelists as they discuss what these combined therapeutic approaches mean to patients, the pharma industry, and the emerging companies working to bring new cancer therapies into clinical development. Moderator: Janet L. Dally, Founder, Maidstone Life Sciences
|
1:15pm-2:00pm |
Summit Showcase
|
1:15pm-3:15pm |
Partnering Forum |
2:15pm-3:15pm |
Workshop: There comes a time when management of an emerging life science company needs to reach beyond their internal team and build their external team to continue their progress toward getting an asset approved. From financial advisers to regulatory consultants, legal advisors and communications specialists, assembling the right team can be daunting. This panel will cover some of the basics about identifying when and which external advisors you need and how you should identify who will be the right fit. Moderator: Claudia Hirawat, President, PTC Therapeutics, Inc. (retired)
|
2:15pm-3:30pm |
Summit Showcase
|
3:15pm-3:30pm | Break |
3:30pm-4:30pm |
Workshop: You’ve finally got the right partner, the right development commitment and the right terms. Negotiating the nitty-gritty of a contract may seem like an after-thought. But the small details in a contract can have big effects down the line. This panel will cover how to position your asset in a contract as well as the road-bumps and land-mines that have tripped up other companies that you need to be aware of so you won’t regret the contract in the morning. Moderator: Brian P. O’Shaughnessy, Shareholder, RatnerPrestia, and Public Policy & Regional Vice President, Licensing Executives Society (LES)
|
3:30pm-4:15pm | Partnering Forum |
3:30pm-4:30pm |
Summit Showcase
|
4:30pm-5:30pm |
Plenary Session: Understanding How Potential Partners & Investors Look at Valuation of Early Stage Assets Placing a value on assets you have spent years developing is a difficult task for the innovator-entrepreneur. But ultimately the value of any asset is the price a partner or investor is willing to pay for it. This panel will discuss how ‘buyers’ approach establishing a value for early stage assets and provide valuable insight into what the guy across the table is thinking. Moderator: Ellen B. Corenswet, Partner, Covington & Burling
|
5:30pm-7:00pm | Reception & Pipeline Café |
Wednesday, December 2, 2015
8:00am-3:00pm | Registration |
8:00am-9:00am | Pipeline Café |
9:00am-10:00am |
Plenary Session: The Early Stage Funding Ecosystem – Angels, VCs, Family Offices, Government, MRFs, and Others In the midst of the hype about a biotech investment bubble it can be easy to forget that funding for early stage companies is still hard to come by – unless you are an early stage company. In the aftermath of the financial crisis new investment options emerged including angel networks, family offices and medical research foundations. Now that the market has recovered, these new players continue to provide crucial funding for early stage biotechs. This panel will discuss the evolution of the financing ecosystem and how to access it. Moderator: Joseph V. Gulfo, MD, MBA, Rothman Institute of Innovation & Entrepreneurship, Fairleigh Dickinson University
|
10:00am-11:00am |
Metabolic Disease: Personal Choice or Destiny? More than one quarter of the world’s adults are living with so called “Life Style” diseases such as obesity, type II diabetes, cardiovascular disease and fatty liver disease. While numerous drugs currently exist to treat diabetes and cardiovascular issues, the demand for them continues as our aging and increasingly obese population fuels market demand. Obesity, fatty liver disease (steatosis), and its more severe form: NASH (non-alcoholic steatohepatitis), have been more challenging targets for drug development. What approaches are showing the most promise for the development of new therapies and where are the breakthroughs occurring? Key Leaders will discuss these issues and provide insights into our changing understanding of the underlying biology and the business forces that will inform future development. Moderator: Stephen D. Wolpe, PhD, Entrepreneur-in-Residence, BioHealth Innovation
|
10:00am-11:00am |
Summit Showcase
|
10:00am-12:00pm |
Partnering Forum |
11:00am-12:00pm |
Workshop: When it comes to determining value of an asset, the strength of the intellectual property that backs it up is one of the most important considerations. This workshop will discuss key issues about how the state of the underlying IP drives value. Moderator: Deborah A. Somerville, Partner, Kenyon & Kenyon LLP
|
11:00am-12:00pm |
Summit Showcase
|
12:00pm-1:15 pm | Lunch with the Experts |
12:00pm-1:15pm | Pipeline Café |
1:15pm-2:15pm |
Summit Showcase
|
1:15pm-2:30pm | Strategic Partner Showcase |
1:15pm-3:15pm | Partnering Forum |
2:15pm-3:15pm |
Workshop: It’s obvious to you why your technology and/or your company deserves funding, but it’s not obvious to everyone else. This workshop will discuss how best to translate your years of work into a ten-second elevator pitch that will impress investors. Getting your story down to a compelling pitch is one of the most difficult tasks that a management team has to undertake and it is often overlooked. This panel will discuss how to express your story and winnow it down to effectively communicate your company value. Moderator: Gregory Q. Tiberend, President & CEO, Tiberend Strategic Advisors, Inc.
|
2:15pm-3:30pm |
Summit Showcase
|
3:15pm-3:30pm | Break |
3:30pm-4:30pm |
Summit Showcase
|
3:30pm-4:15pm | Strategic Partner Showcase |
3:30pm-4:15pm | Partnering Forum |
4:30pm-5:30pm |
Plenary Session & Closing Reception: Pharma & Big Bio’s Appetite for Early Innovation Pharmaceutical, and increasingly Big Bio, companies regularly look outside their organizations for innovation, but what are they looking for and where are they looking? This panel of biopharma industry veterans will discuss how they approach accessing early stage innovation and how a scientific innovator can position their technology to attract the attention of a buyer. Moderator: Tim Opler, Partner, Torreya Partners
|
Plenary |
KOLs |
Workshops |
Showcase |